Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.0057 | 1 | 0.5 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0057 | 1 | 0.5 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0057 | 1 | 1 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.0057 | 1 | 1 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0057 | 1 | 0.5 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.0057 | 1 | 0.5 |
Mycobacterium ulcerans | proteasome PrcB | 0.0057 | 1 | 0.5 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0057 | 1 | 1 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.0057 | 1 | 0.5 |
Onchocerca volvulus | 0.0041 | 0.3658 | 0.5 | |
Schistosoma mansoni | inhibitor of apoptosis protein | 0.0041 | 0.3658 | 0.3658 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0057 | 1 | 0.5 |
Schistosoma mansoni | inhibitor of apoptosis (iap) domain family member | 0.0041 | 0.3658 | 0.3658 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.3658 | 0.3658 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0057 | 1 | 0.5 |
Echinococcus granulosus | proteasome prosome macropain | 0.0057 | 1 | 1 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.0057 | 1 | 1 |
Onchocerca volvulus | Deterin homolog | 0.0041 | 0.3658 | 0.5 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0057 | 1 | 0.5 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.0057 | 1 | 0.5 |
Mycobacterium tuberculosis | Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. | 0.0057 | 1 | 0.5 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0057 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.